Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism, subscribe today.
When the first COVID-19 vaccines reach market, the world will not necessarily return to ‘normal,’ say top infectious disease experts.
In a new article for the Lancet medical journal, two University of Hong Kong researchers caution that even at the conclusion of phase III clinical trials, important questions will remain about how effective vaccines are in stopping viral transmission of COVID-19.
Gabriel Leung, an infectious disease epidemiologist, and Malik Peiris, a public health virologist, argue that even though multiple vaccine makers have reached phase III clinical trials at a record pace, scientists are currently only studying part of the equation in gauging how a vaccine may help bring an end to the global pandemic.